225 related articles for article (PubMed ID: 35190446)
1. Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study).
Lam V; Clarnette R; Francis R; Bynevelt M; Watts G; Flicker L; Orr CF; Loh P; Lautenschlager N; Reid CM; Foster JK; Dhaliwal SS; Robinson S; Corti E; Vaccarezza M; Horgan B; Takechi R; Mamo J
BMJ Open; 2022 Feb; 12(2):e058826. PubMed ID: 35190446
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.
Devanand DP; Andrews H; Kreisl WC; Razlighi Q; Gershon A; Stern Y; Mintz A; Wisniewski T; Acosta E; Pollina J; Katsikoumbas M; Bell KL; Pelton GH; Deliyannides D; Prasad KM; Huey ED
BMJ Open; 2020 Feb; 10(2):e032112. PubMed ID: 32034019
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of 3-month melatonin supplementation for brain oxidative stress and sleep in mild cognitive impairment: protocol for a randomised, placebo-controlled study.
Menczel Schrire Z; Phillips CL; Duffy SL; Marshall NS; Mowszowski L; La Monica HM; Gordon CJ; Chapman JL; Saini B; Lewis SJG; Naismith SL; Grunstein RR; Hoyos CM
BMJ Open; 2021 Feb; 11(2):e041500. PubMed ID: 33568368
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
[TBL] [Abstract][Full Text] [Related]
7. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
8. Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.
Vivash L; Bertram KL; Malpas CB; Marotta C; Harding IH; Kolbe S; Fielding J; Clough M; Lewis SJG; Tisch S; Evans AH; O'Sullivan JD; Kimber T; Darby D; Churilov L; Law M; Hovens CM; Velakoulis D; O'Brien TJ
BMJ Open; 2021 Dec; 11(12):e055019. PubMed ID: 34916328
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.
Possemis N; Verhey F; Prickaerts J; Blokland A; Ramakers I
Trials; 2024 Mar; 25(1):162. PubMed ID: 38438923
[TBL] [Abstract][Full Text] [Related]
12. Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease.
Holper S; Watson R; Churilov L; Yates P; Lim YY; Barnham KJ; Yassi N
J Prev Alzheimers Dis; 2023; 10(4):800-809. PubMed ID: 37874102
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
14. Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
Koychev I; Adler AI; Edison P; Tom B; Milton JE; Butchart J; Hampshire A; Marshall C; Coulthard E; Zetterberg H; Hellyer P; Cormack F; Underwood BR; Mummery CJ; Holman RR
BMJ Open; 2024 Jun; 14(6):e081401. PubMed ID: 38908839
[TBL] [Abstract][Full Text] [Related]
15. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
16. Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
Kondo T; Banno H; Okunomiya T; Amino Y; Endo K; Nakakura A; Uozumi R; Kinoshita A; Tada H; Morita S; Ishikawa H; Shindo A; Yasuda K; Taruno Y; Maki T; Suehiro T; Mori K; Ikeda M; Fujita K; Izumi Y; Kanemaru K; Ishii K; Shigenobu K; Kutoku Y; Sunada Y; Kawakatsu S; Shiota S; Watanabe T; Uchikawa O; Takahashi R; Tomimoto H; Inoue H
BMJ Open; 2021 Jun; 11(6):e051343. PubMed ID: 34193504
[TBL] [Abstract][Full Text] [Related]
17. A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.
Vivash L; Malpas CB; Churilov L; Walterfang M; Brodtmann A; Piguet O; Ahmed RM; Bush AI; Hovens CM; Kalincik T; Darby D; Velakoulis D; O'Brien TJ
BMJ Open; 2020 Nov; 10(11):e040100. PubMed ID: 33199422
[TBL] [Abstract][Full Text] [Related]
18. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice.
Santos DB; Peres KC; Ribeiro RP; Colle D; dos Santos AA; Moreira EL; Souza DO; Figueiredo CP; Farina M
Exp Neurol; 2012 Feb; 233(2):767-75. PubMed ID: 22173317
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
20. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
